Every material Form 8-K Nurix Therapeutics, Inc. has filed with the SEC since July 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nurix Therapeutics said on November 3, 2026 that collaboration partner Sanofi has discontinued the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminated the program. As a result, Nurix does not expect to receive the development, regulatory and commercial milestone payments or royalties it was eligible for on that program, though it remains eligible for payments on other licensed programs under the Sanofi collaboration.
Sanofi notified Nurix on November 3, 2026 that it is discontinuing the Phase 1 first-in-human trial of SAR448272 and terminating the program
Nurix does not expect any future development, regulatory or commercial milestone payments or royalties tied to SAR448272
Nurix remains eligible for milestones and royalties on other licensed programs, which Sanofi may further develop at its discretion
Nurix Therapeutics reported results for the fiscal quarter ended August 31, 2026. Total revenue rose to $673.1 million from $7.9 million a year earlier, mainly from $653.2 million of license revenue tied to the Roche collaboration, and the company reported net income of $549.8 million, or $4.73 per diluted share, compared with a net loss of $86.4 million a year earlier. Because most of the revenue came from a single license payment, the filing's profit figures are driven by that item rather than by recurring sales.
Total revenue was $673.1 million, versus $7.9 million a year earlier, including $653.2 million of Roche license revenue.
Net income was $549.8 million, or $4.73 per diluted share, versus a net loss of $86.4 million, or $1.03 per share, a year earlier.
General and administrative expenses rose to $34.4 million from $13.2 million, mainly due to one-time Roche transaction costs.
Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, versus $592.9 million on November 30, 2025.
For the fiscal second quarter ended May 31, 2026, Nurix reported revenue of $9.0 million, down from $44.1 million a year earlier, and a net loss of $89.5 million ($0.81 per share), up from $43.5 million ($0.52 per share). The company also announced a global collaboration with Roche for bexobrutideg, with a $700 million upfront payment expected within 30 days after the agreement takes effect, subject to antitrust clearances.
Revenue was $9.0 million versus $44.1 million; the prior-year period included $30 million of license revenue from two Sanofi license extensions.
Net loss was $89.5 million, or $0.81 per share, compared with $43.5 million, or $0.52 per share, a year earlier.
Roche collaboration covers bexobrutideg with potential total payments of up to $2.3 billion, including the $700 million upfront payment; closing requires Hart-Scott-Rodino clearance and other antitrust clearances.
Cash, cash equivalents and marketable securities were $443.5 million at May 31, 2026, versus $592.9 million at November 30, 2025; the company expects the Roche upfront payment in its third fiscal quarter of 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Nurix Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →